- Home
- XOS vs TPST Comparison
XOS vs TPST Comparison
Compare XOS & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOS
- TPST
- Stock Information
- Founded
- XOS 2016
- TPST 2011
- Country
- XOS United States
- TPST United States
- Employees
- XOS N/A
- TPST N/A
- Industry
- XOS Construction/Ag Equipment/Trucks
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- XOS Consumer Discretionary
- TPST Health Care
- Exchange
- XOS Nasdaq
- TPST Nasdaq
- Market Cap
- XOS 25.6M
- TPST 33.0M
- IPO Year
- XOS N/A
- TPST N/A
- Fundamental
- Price
- XOS $3.51
- TPST $6.71
- Analyst Decision
- XOS Buy
- TPST Hold
- Analyst Count
- XOS 5
- TPST 3
- Target Price
- XOS $8.80
- TPST $30.00
- AVG Volume (30 Days)
- XOS 17.7K
- TPST 73.0K
- Earning Date
- XOS 08-12-2025
- TPST 08-07-2025
- Dividend Yield
- XOS N/A
- TPST N/A
- EPS Growth
- XOS N/A
- TPST N/A
- EPS
- XOS N/A
- TPST N/A
- Revenue
- XOS $48,678,000.00
- TPST N/A
- Revenue This Year
- XOS $1.45
- TPST N/A
- Revenue Next Year
- XOS $27.16
- TPST N/A
- P/E Ratio
- XOS N/A
- TPST N/A
- Revenue Growth
- XOS N/A
- TPST N/A
- 52 Week Low
- XOS $2.73
- TPST $5.35
- 52 Week High
- XOS $9.15
- TPST $29.38
- Technical
- Relative Strength Index (RSI)
- XOS 56.51
- TPST 44.06
- Support Level
- XOS $3.30
- TPST $6.57
- Resistance Level
- XOS $3.50
- TPST $7.05
- Average True Range (ATR)
- XOS 0.14
- TPST 0.26
- MACD
- XOS 0.04
- TPST -0.05
- Stochastic Oscillator
- XOS 72.00
- TPST 15.90
About XOS Xos Inc.
Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Classes 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.